Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant’s Brodalumab Delayed By FDA As REMS Is Negotiated

Executive Summary

FDA notified the company the US review goal date for the psoriasis pill has been extended three months from Nov. 16 to Feb. 16.


Related Content

Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Siliq US Approval Expected To Make Little Dent In Valeant Debt Mountain
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
Valeant Is Weighing Offers For Assets As Stocks Plunges Again
Another Black Cloud Douses Valeant's Sunlight
Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment
Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?
Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch
Amgen dumps brodalumab; AstraZeneca losing a blockbuster?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts